Targeting the adenosine 2A receptor in non-small cell lung cancer: shooting with blank bullets?
作者信息
Garcia-Lorenzo Esther, Moreno Victor
机构信息
START Madrid-FJD, Early Phase Clinical Trials Unit, Hospital Fundación Jiménez Díaz, Madrid, Spain.
出版信息
Transl Lung Cancer Res. 2023 Apr 28;12(4):653-656. doi: 10.21037/tlcr-23-38. Epub 2023 Apr 6.
Abstract
摘要
相似文献
1
Targeting the adenosine 2A receptor in non-small cell lung cancer: shooting with blank bullets?靶向非小细胞肺癌中的腺苷2A受体：放空枪？
Transl Lung Cancer Res. 2023 Apr 28;12(4):653-656. doi: 10.21037/tlcr-23-38. Epub 2023 Apr 6.
2
Disruption of adenosine 2A receptor improves the anti-tumor function of anti-mesothelin CAR T cells both in vitro and in vivo.腺苷 2A 受体的破坏可提高抗间皮素 CAR T 细胞的抗肿瘤功能，无论是在体外还是体内。
Exp Cell Res. 2021 Dec 1;409(1):112886. doi: 10.1016/j.yexcr.2021.112886. Epub 2021 Oct 19.
3
Genetic and pharmacological targeting of A2a receptor improves function of anti-mesothelin CAR T cells.靶向 A2a 受体的遗传和药理学方法可改善抗间皮素 CAR T 细胞的功能。
J Exp Clin Cancer Res. 2020 Mar 10;39(1):49. doi: 10.1186/s13046-020-01546-6.
4
Prognostic impact of CD73 and A2A adenosine receptor expression in non-small-cell lung cancer.CD73和A2A腺苷受体表达对非小细胞肺癌的预后影响
Oncotarget. 2017 Jan 31;8(5):8738-8751. doi: 10.18632/oncotarget.14434.
5
CD39/CD73/A2AR pathway and cancer immunotherapy.CD39/CD73/A2AR 通路与癌症免疫治疗。
Mol Cancer. 2023 Mar 2;22(1):44. doi: 10.1186/s12943-023-01733-x.
6
Pharmacological targeting of immune checkpoint A2aR improves function of anti-CD19 CAR T cells in vitro.免疫检查点 A2aR 的药理学靶向作用可改善体外抗 CD19 CAR T 细胞的功能。
Immunol Lett. 2020 Jul;223:44-52. doi: 10.1016/j.imlet.2020.04.005. Epub 2020 Apr 11.
7
Adenosine-A2A Receptor Pathway in Cancer Immunotherapy.癌症免疫治疗中的腺苷 - A2A 受体通路
Front Immunol. 2022 Mar 21;13:837230. doi: 10.3389/fimmu.2022.837230. eCollection 2022.
8
A Novel Antagonist of the Immune Checkpoint Protein Adenosine A2a Receptor Restores Tumor-Infiltrating Lymphocyte Activity in the Context of the Tumor Microenvironment.一种新型免疫检查点蛋白腺苷A2a受体拮抗剂可在肿瘤微环境中恢复肿瘤浸润淋巴细胞活性。
Neoplasia. 2017 Jul;19(7):530-536. doi: 10.1016/j.neo.2017.02.004. Epub 2017 Jun 3.
9
Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer.腺苷 A2A 受体阻断作为治疗抵抗性肾细胞癌的免疫疗法。
Cancer Discov. 2020 Jan;10(1):40-53. doi: 10.1158/2159-8290.CD-19-0980. Epub 2019 Nov 15.
10
Small molecule AZD4635 inhibitor of AR signaling rescues immune cell function including CD103 dendritic cells enhancing anti-tumor immunity.小分子 AR 信号抑制剂 AZD4635 可恢复免疫细胞功能，包括 CD103 树突状细胞，增强抗肿瘤免疫。
J Immunother Cancer. 2020 Jul;8(2). doi: 10.1136/jitc-2019-000417.
引用本文的文献
1
Tumour and microenvironment crosstalk in NSCLC progression and response to therapy.非小细胞肺癌进展及对治疗反应中的肿瘤与微环境相互作用
Nat Rev Clin Oncol. 2025 May 16. doi: 10.1038/s41571-025-01021-1.
2
Caffeine-folic acid-loaded-chitosan nanoparticles combined with methotrexate as a novel HepG2 immunotherapy targeting adenosine A2A receptor downstream cascade.载咖啡酸叶酸壳聚糖纳米粒联合甲氨蝶呤作为一种新型以腺苷 A2A 受体下游级联为靶点的 HepG2 免疫治疗药物。
BMC Complement Med Ther. 2023 Oct 27;23(1):384. doi: 10.1186/s12906-023-04212-4.
本文引用的文献
1
Oncogene alterations in non-small cell lung cancer-have we a new target?非小细胞肺癌中的癌基因改变——我们有新靶点了吗？
Transl Lung Cancer Res. 2022 Oct;11(10):1977-1981. doi: 10.21037/tlcr-22-648.
2
Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non-Small Cell Lung Cancer.塔米纳丹（PBF509/NIR178）联合或不联合斯巴达珠单抗（PDR001）治疗晚期非小细胞肺癌的 I 期研究
Clin Cancer Res. 2022 Jun 1;28(11):2313-2320. doi: 10.1158/1078-0432.CCR-21-2742.
3
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.Relatlimab 和 Nivolumab 对比 Nivolumab 用于未经治疗的晚期黑色素瘤。
N Engl J Med. 2022 Jan 6;386(1):24-34. doi: 10.1056/NEJMoa2109970.
4
Correction to: "Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up".对《转移性非小细胞肺癌：ESMO诊断、治疗及随访临床实践指南》的勘误
Ann Oncol. 2019 May;30(5):863-870. doi: 10.1093/annonc/mdy474. Epub 2019 Dec 4.
5
Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer.腺苷 A2A 受体阻断作为治疗抵抗性肾细胞癌的免疫疗法。
Cancer Discov. 2020 Jan;10(1):40-53. doi: 10.1158/2159-8290.CD-19-0980. Epub 2019 Nov 15.
6
Cancer statistics, 2019.癌症统计数据，2019 年。
CA Cancer J Clin. 2019 Jan;69(1):7-34. doi: 10.3322/caac.21551. Epub 2019 Jan 8.
7
Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.IV 期非小细胞肺癌的系统治疗：美国临床肿瘤学会临床实践指南更新。
J Clin Oncol. 2017 Oct 20;35(30):3484-3515. doi: 10.1200/JCO.2017.74.6065. Epub 2017 Aug 14.
8
A Novel Antagonist of the Immune Checkpoint Protein Adenosine A2a Receptor Restores Tumor-Infiltrating Lymphocyte Activity in the Context of the Tumor Microenvironment.一种新型免疫检查点蛋白腺苷A2a受体拮抗剂可在肿瘤微环境中恢复肿瘤浸润淋巴细胞活性。
Neoplasia. 2017 Jul;19(7):530-536. doi: 10.1016/j.neo.2017.02.004. Epub 2017 Jun 3.
9
Targeting adenosine in cancer immunotherapy: a review of recent progress.癌症免疫治疗中靶向腺苷：近期进展综述
Expert Rev Anticancer Ther. 2017 Jun;17(6):527-535. doi: 10.1080/14737140.2017.1316197. Epub 2017 Apr 27.
10
Co-inhibition of CD73 and A2AR Adenosine Signaling Improves Anti-tumor Immune Responses.抑制 CD73 和 A2AR 腺苷信号可改善抗肿瘤免疫反应。
Cancer Cell. 2016 Sep 12;30(3):391-403. doi: 10.1016/j.ccell.2016.06.025.
Zotero 插件